


Rho-Kinase-IN-1

Cat. No.:	HY-100270		
CAS No.:	1035094-83-7		
Molecular Formula:	C ₂₀ H ₂₄ N ₄ S		
Molecular Weight:	352.5		
Target:	ROCK		
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (141.84 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.8369 mL	14.1844 mL	28.3688 mL
		5 mM	0.5674 mL	2.8369 mL	5.6738 mL
10 mM		0.2837 mL	1.4184 mL	2.8369 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.90 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.90 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.90 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Rho-Kinase-IN-1 is a Rho kinase (ROCK) inhibitor (K _i values of 30.5 and 3.9 nM for ROCK1 and ROCK2, respectively) extracted from US20090325960A1, compound 1.008 ^[1] .	
IC₅₀ & Target	ROCK1 30.5 nM (K _i)	ROCK2 3.9 nM (K _i)
In Vitro	Rho-Kinase-IN-1 is a ROCK inhibitor which can be useful for treating diseases or conditions associated with excessive cell	

proliferation, remodeling, edema and inflammation^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Fulcher, Emilee H, et al. Method for the treatment and prevention of the inflammatory diseases using Rho kinase inhibiting compounds. US 20090325960 A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA